ライフサイエンスコーパス: inhaled corticosteroid

1 with mild active asthma (8/10 were not using inhaled corticosteroids).

2 with combined long-acting beta2-agonists and inhaled corticosteroids.

3 osinophilia despite treatment with high-dose inhaled corticosteroids.

4 ome, environmental tobacco smoke, and use of inhaled corticosteroids.

5 overall mortality associated with the use of inhaled corticosteroids.

6 mptomatic despite treatment with medium-dose inhaled corticosteroids.

7 eterol 50 mug, or placebo, while maintaining inhaled corticosteroids.

8 h an asthma exacerbation and were on regular inhaled corticosteroids.

9 dherence with controller medications such as inhaled corticosteroids.

10 a refractory to maximally indicated doses of inhaled corticosteroids.

11 All patients continued their inhaled corticosteroids.

12 d severity of asthma and a lower response to inhaled corticosteroids.

13 as an add-on therapy in adult asthmatics on inhaled corticosteroids.

14 es with the addition of INCS spray to orally inhaled corticosteroids.

15 f asthma exacerbations and used less oral or inhaled corticosteroids.

16 ikizumab in asthmatic patients not receiving inhaled corticosteroids.

17 ma previously receiving medium- to high-dose inhaled corticosteroids.

18 e alterations are only modestly corrected by inhaled corticosteroids.

19 th muscle compared to those not treated with inhaled corticosteroids.

20 ave higher morbidity and reduced response to inhaled corticosteroids.

21 may partly explain their reduced response to inhaled corticosteroids.

22 thelial cells recovered after treatment with inhaled corticosteroids.

23 evious 12 months and who were not on regular inhaled corticosteroids.

24 respiratory symptoms to predict response to inhaled corticosteroids.

25 es) and whether or not patients had received inhaled corticosteroids.

26 ounts less than 2% have a poorer response to inhaled corticosteroids.

27 r rapid relief of symptoms, and daily use of inhaled corticosteroids.

28 ss in adult stable asthmatic patients taking inhaled corticosteroids.

29 ent failure, particularly in subjects taking inhaled corticosteroids.

30 -naive subjects with asthma before and after inhaled corticosteroids, 19 steroid-using subjects with

31 ators (16.7%; 95% CI: 16.1%-17.3%; p<0.001), inhaled corticosteroids (21.5%; 95% CI: 20.7%-22.3%; p<0

32 mproved therapeutic ratio over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and pr

33 s observed among 5594 new users of LABAs and inhaled corticosteroids (3174 deaths [36.4%]; 2420 COPD

34 In patients not treated with inhaled corticosteroids, 40 (3.8%) patients with less th

35 un-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized.

36 uncontrolled wheezing despite high doses of inhaled corticosteroids (55%), parents with asthma, and

37 r a short-acting beta2-agonist and 41.2% for inhaled corticosteroids; 76.5% were managed with asthma

38 strong recommendations were made for a daily inhaled corticosteroid, a daily leukotriene receptor ant

39 In the intention-to-treat analysis, inhaled corticosteroid adherence was 25.4% higher in the

40 -agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient.

41 article formulations (smaller than 2 mum) of inhaled corticosteroids alone or in combination with lon

42 lus orally inhaled corticosteroids to orally inhaled corticosteroids alone, and nasally inhaled corti

43 n patients with moderate-to-severe asthma on inhaled corticosteroid and long-acting beta(2)-agonist b

44 nist (LAMA), licensed as triple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS

45 iven orally once daily together with a fixed inhaled corticosteroid and longacting beta2 agonist comb

46 of frequent and severe exacerbations despite inhaled corticosteroid and longacting beta2 agonist ther

47 for exacerbations, even in combination with inhaled corticosteroid and longacting beta2 agonist trea

48 ons, we analysed 214 patients (114 extrafine inhaled corticosteroids and 100 placebo).

49 in patients with uncontrolled asthma despite inhaled corticosteroids and at least one second controll

50 upport further study to test the efficacy of inhaled corticosteroids and beta agonists for prevention

51 Early treatment with inhaled corticosteroids and beta agonists may reduce pro

52 esponder group who were exposed to high-dose inhaled corticosteroids and frequent long-acting beta-ag

53 t as allergic patients using antihistamines, inhaled corticosteroids and IgE antagonists.

54 The association of use of inhaled corticosteroids and incident pneumonia is substa

55 asthma who remain symptomatic despite taking inhaled corticosteroids and long-acting beta(2)-agonists

56 regimens, including the more flexible use of inhaled corticosteroids and long-acting beta-agonists in

57 patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting beta-agonists.

58 Inhaled corticosteroids and long-acting beta2-agonist co

59 least two exacerbations while on high-dosage inhaled corticosteroids and long-acting beta2-agonists (

60 tion for high-intensity treatment (high-dose inhaled corticosteroids and long-acting beta2-agonists o

61 Combination therapy, including inhaled corticosteroids and long-acting beta2-agonists,

62 rolled asthma using medium-dose or high-dose inhaled corticosteroids and longacting beta agonists, wi

63 Current therapies based on inhaled corticosteroids and longacting beta2 agonists ar

64 fect in patients using fixed combinations of inhaled corticosteroids and longacting beta2 agonists is

65 avir) can result in systemic accumulation of inhaled corticosteroids and might increase pneumonia ris

66 lammation and might respond to high doses of inhaled corticosteroids and newly developed specific ant

67 rimary outcomes were adherence to preventive inhaled corticosteroids and number of days absent from s

68 Total doses of inhaled corticosteroids and oral corticosteroids (OCSs)

69 ided the rationale for disease control using inhaled corticosteroids and other anti-inflammatory drug

70 litation and bronchodilators with or without inhaled corticosteroids and oxygen; those randomized to

71 dentify patients most likely to benefit from inhaled corticosteroids and targeted anti-immunoglobulin

72 60-90% predicted despite use of medium-dose inhaled corticosteroids, and had never smoked or were ex

73 thma morbidity, lower drug responsiveness to inhaled corticosteroids, and worse asthma control.

74 Once-daily longacting beta-agonists and inhaled corticosteroids are being developed.

75 Inhaled corticosteroids are commonly prescribed for pati

76 Inhaled corticosteroids are commonly used in the treatme

77 Inhaled corticosteroids are important in the management

78 Inhaled corticosteroids are the most commonly used contr

79 Few treatments are available and inhaled corticosteroids are the recommended preventer tr

80 Inhaled corticosteroids are widely used in chronic obstr

81 nical trials of patients with COPD that had: inhaled corticosteroid arms (fluticasone propionate and

82 o salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a posit

83 ciated with increased risk of treatment with inhaled corticosteroids at age 7 years (adjusted odds ra

84 able asthmatics that were being treated with inhaled corticosteroids at the time of the study.

85 uately controlled by medium-to-high doses of inhaled corticosteroid based therapy and who had blood e

86 with good responders and poor responders to inhaled corticosteroids based on a subset of 145 white c

87 il counts who are inadequately controlled on inhaled corticosteroid-based therapy.

88 er medications after the use of high-potency inhaled corticosteroids became common.

89 A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps

90 t asthma exacerbations and responsiveness to inhaled corticosteroids but are impractical to measure i

91 lergic inflammation that was unresponsive to inhaled corticosteroids, but responsive to systemic cort

92 y asthma therapies (leukotriene antagonists, inhaled corticosteroids) can safely mitigate the sequela

93 matching, there were 8712 new users of LABA-inhaled corticosteroid combination therapy and 3160 new

94 nergic medication, newly prescribed LABA and inhaled corticosteroid combination therapy, compared wit

95 ncy than either their monocomponents or LABA/inhaled corticosteroid combinations in patients at low a

96 GROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-

97 cting beta2-agonists or medium- to high-dose inhaled corticosteroids combined with oral corticosteroi

98 Inhaled corticosteroids continue to be the mainstay for

99 rategies for persistent asthma include daily inhaled corticosteroids, daily leukotriene receptor anta

100 Poor persistence to inhaled corticosteroids, defined as a gap of up to 60 da

101 Patients using inhaled corticosteroids displayed significantly lower nu

102 (Fe(NO)) suppression after directly observed inhaled corticosteroid (DOICS) treatment.

103 sthma Control Questionnaire score, 0.76; and inhaled corticosteroid dosage, 550 mug/d.

104 s with mild to moderate asthma undergoing an inhaled corticosteroid dose reduction do not support the

105 ypes was not influenced by change in oral or inhaled corticosteroid dose, nor by the number of exacer

106 elated (P < .05 for all) positively with the inhaled corticosteroid dose, total number of controller

107 BT, despite a 18% reduction in average daily inhaled corticosteroid dose.

108 Use of inhaled corticosteroids during the first trimester of pr

109 have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chr

110 In patients treated with inhaled corticosteroids, events occurred in 107 (4.5%) v

111 The SMART regimen resulted in higher inhaled corticosteroid exposure (943.5 mug budesonide pe

112 ful biomarker of the long-term effect of the inhaled corticosteroid fluticasone furoate on exacerbati

113 evert toward baseline after therapy with the inhaled corticosteroid fluticasone in independent cohort

114 Across all doses of inhaled corticosteroids, fluticasone furoate and vilante

115 ticle salmeterol dry powder twice daily plus inhaled corticosteroid for 1 to 2 weeks with a 1- to 2-w

116 The short-term benefits of inhaled corticosteroids for patients with chronic obstru

117 the change in ACQ7 greater in the extrafine inhaled corticosteroids group than in the placebo group

118 Treatment with inhaled corticosteroids had modest effects on miRNA expr

119 rse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperres

120 However, inhaled corticosteroids have been linked with an increas

121 RATIONALE: Inhaled corticosteroids have been shown to decrease exac

122 high blood eosinophil counts despite use of inhaled corticosteroids have reported improved outcomes

123 hese observations suggest a double effect of inhaled corticosteroids (i.e., an adverse effect plus an

124 esponsiveness to step-up to a higher dose of inhaled corticosteroid (ICS step-up therapy) or addition

125 ly 36% of subjects with asthma not taking an inhaled corticosteroid (ICS) and 17% of ICS-treated subj

126 contribute to uncontrolled asthma; negative inhaled corticosteroid (ICS) beliefs and complementary a

127 umab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall e

128 been a general expectation that early use of inhaled corticosteroid (ICS) could change the natural hi

129 Asthma guidelines recommend inhaled corticosteroid (ICS) dose titration for patients

130 izumab and placebo groups during the 16-week inhaled corticosteroid (ICS) dose-stable phase were eval

131 study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) an

132 pium is an effective treatment when added to inhaled corticosteroid (ICS) maintenance therapy.

133 d n = 20 control subjects) and prediction of inhaled corticosteroid (ICS) response (n = 71 asthmatic

134 ty (OW) is linked to worse asthma and poorer inhaled corticosteroid (ICS) response in older children

135 sks for infants and young children receiving inhaled corticosteroid (ICS) therapy are largely unknown

136 Inhaled corticosteroid (ICS) therapy is a mainstay of tr

137 cs who smoke cigarettes respond less well to inhaled corticosteroid (ICS) therapy than asthmatics who

138 mptoms and a low risk of asthma attacks with inhaled corticosteroid (ICS) treatment.

139 tion in sputum basophils following increased inhaled corticosteroid (ICS) treatment.

140 uggested an increased risk of pneumonia with inhaled corticosteroid (ICS) use, although this associat

141 ssociation was modified by smoking status or inhaled corticosteroid (ICS) use.

142 The rate of discontinuation of inhaled corticosteroid (ICS) was 6/17 in SCIT + vitamin

143 Their use of inhaled corticosteroid (ICS) was standardized and adjust

144 ay contribute to the clinical superiority of inhaled corticosteroid (ICS)/LABA combinations in asthma

145 ized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (

146 nists (LABAs) (n = 3174), 1 RCT of LABAs and inhaled corticosteroids (ICS) (n = 1097), 5 RCTs of the

147 BACKGROUND AND Inhaled corticosteroids (ICS) and inhaled corticosteroid

148 Side-effect concerns impede adherence with inhaled corticosteroids (ICS) and often underlie poor as

149 Low-dose inhaled corticosteroids (ICS) are highly effective for r

150 exacerbation in stable asthmatics who reduce inhaled corticosteroids (ICS) compared to those who main

151 ive pulmonary disease (COPD) who were taking inhaled corticosteroids (ICS) concomitantly, whereas pat

152 an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization.

153 re two principal agents that can be added to inhaled corticosteroids (ICS) for patients with asthma t

154 The NHLBI Expert Panel Report 3 recommends inhaled corticosteroids (ICS) for patients with moderate

155 eosinophil counts might predict response to inhaled corticosteroids (ICS) in patients with chronic o

156 Inhaled corticosteroids (ICS) increase community-acquire

157 The clinical response to inhaled corticosteroids (ICS) is associated with single

158 been receiving either low- to medium-dosage inhaled corticosteroids (ICS) or low-dosage ICS plus lon

159 Inhaled corticosteroids (ICS) target gene transcription

160 ained from 25 normal controls, eight mild/no inhaled corticosteroids (ICS), 16 mild-moderate/with ICS

161 ts with asthma on maintenance treatment with inhaled corticosteroids (ICS).

162 se to salmeterol was dependent on the use of inhaled corticosteroids (ICS).

163 most commonly prescribed controller therapy, inhaled corticosteroids (ICS).

164 Inhaled corticosteroids (ICSs) are considered the most e

165 istent asthma during pregnancy when low-dose inhaled corticosteroids (ICSs) are insufficient include

166 Inhaled corticosteroids (ICSs) are the preferred treatme

167 Inhaled corticosteroids (ICSs) are used extensively in t

168 Inhaled corticosteroids (ICSs) are widely used as first-

169 a exacerbation in patients who stop low-dose inhaled corticosteroids (ICSs) compared with those who c

170 Characteristics of inhaled corticosteroids (ICSs) differ, but data comparin

171 receptor antagonists (LTRAs) in addition to inhaled corticosteroids (ICSs) in asthmatic patients pro

172 dynamic assessment of the systemic effect of inhaled corticosteroids (ICSs) is often done by measurin

173 A allele among the 637 children treated with inhaled corticosteroids (ICSs) plus LABAs but not for tr

174 to obtain diagnoses and treatment), (2) use inhaled corticosteroids (ICSs) properly, and (3) underst

175 atment of mild asthma is regular maintenance inhaled corticosteroids (ICSs) with a short-acting beta-

176 opium is efficacious as an add-on therapy to inhaled corticosteroids (ICSs) with or without other mai

177 ess (AHR), improves with bronchodilators and inhaled corticosteroids (ICSs), and worsens during exace

178 d followed by 3 crossover periods with daily inhaled corticosteroids (ICSs), daily leukotriene recept

179 tic patients using LABA-containing products, inhaled corticosteroids (ICSs), leukotriene modifiers, s

180 When compared with placebo, only inhaled corticosteroids (ICSs), with or without a long-a

181 rican and white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respective

182 Treatment with inhaled corticosteroids improves airway responsiveness a

183 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

184 with two long-acting bronchodilators and an inhaled corticosteroid in chronic obstructive pulmonary

185 nalyzed differences in FEV(1) in response to inhaled corticosteroids in 418 white subjects with asthm

186 r single long-acting bronchodilators or LABA/inhaled corticosteroids in decreasing exacerbation.

187 so associated with lung function response to inhaled corticosteroids in each of the trials associated

188 ancing the beneficial and adverse effects of inhaled corticosteroids in individuals with COPD--is dif

189 ount is a promising biomarker of response to inhaled corticosteroids in patients with COPD.

190 aled nitric oxide (FeNO) and the response to inhaled corticosteroids in patients with non-specific re

191 to significant improvements in adherence to inhaled corticosteroids in school-aged children with ast

192 to physician assessment-based adjustment of inhaled corticosteroids in time to treatment failure.

193 lyses of the Maintenance Versus Intermittent Inhaled Corticosteroids in Wheezing Toddlers trial, invo

194 ither as monotherapy or as add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 per

195 rticosteroid treatment, the magnitude of the inhaled corticosteroid-induced improvement in asthma con

196 tions either enabled to support adherence to inhaled corticosteroids (intervention group) or disabled

197 f acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for pers

198 mechanisms of increased pneumonia risk with inhaled corticosteroids is urgently needed to clarify th

199 o was complicated with COPD and treated with inhaled corticosteroid, long-acting beta2 agonist, long-

200 xed-dose combination inhaler therapy with an inhaled corticosteroid, long-acting beta2-agonist, and l

201 whereas severe disease can be refractory to inhaled corticosteroids, long-acting beta-agonists, and

202 rounding the long-term safety of combination inhaled corticosteroid/long-acting beta(2)-adrenergic ag

203 phils as a predictor of responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combina

204 ts of stepping up patients with COPD from an inhaled corticosteroid/long-acting beta2-agonist combina

205 were randomized (1:1) to 7 (maximum 14) days inhaled corticosteroid/long-acting beta2-agonist flutica

206 tenance and reliever therapy with fixed-dose inhaled corticosteroid/long-acting beta2-agonist therapy

207 izations in the previous year, and receiving inhaled corticosteroid/long-acting beta2-agonist with or

208 erent deficient IFN responses to rhinovirus, inhaled corticosteroids might interact synergistically w

209 agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling diseas

210 nists alone (n = 10) or beta(2)-agonists and inhaled corticosteroids (n = 10).

211 The potential adverse effects of inhaled corticosteroids need to be weighed against the l

212 sociated with more frequent prescriptions of inhaled corticosteroids (odds ratio [OR], 4.4; 95% CI, 1

213 The effects of inhaled corticosteroids on growth seem to be dependent o

214 literature to further explore the effects of inhaled corticosteroids on incident pneumonia and mortal

215 medication use (leukotriene antagonists and inhaled corticosteroids) on the following 4 asthma-relat

216 r development, mainly in combination with an inhaled corticosteroid or a long-acting antimuscarinic a

217 pulations that are more likely to respond to inhaled corticosteroids or biologics.

218 Newly prescribed combination LABAs and inhaled corticosteroids or LABAs alone.

219 tive measurements of children's adherence to inhaled corticosteroids or placebo and to determine whet

220 every year older than age 30 in subjects on inhaled corticosteroids (OR per year, 1.03; CI, 1.01-1.0

221 ombination of long-acting beta2-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85).

222 mass index, vitamin D dosing regimen, use of inhaled corticosteroids, or end-study 25(OH)D levels; po

223 INCS sprays when patients were not on orally inhaled corticosteroids, or when corticosteroid medicati

224 quately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting beta-agonist.

225 vals in addition to standard care (high-dose inhaled corticosteroids plus >/=1 additional controller

226 receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

227 led persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

228 asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist

229 quately controlled disease despite high-dose inhaled corticosteroids plus at least 2 other controller

230 uncontrolled by medium-dosage to high-dosage inhaled corticosteroids plus long-acting beta(2)-agonist

231 nd exacerbation risk when added to high-dose inhaled corticosteroids plus long-acting beta2 agonists.

232 ble safety profile, and hence in addition to inhaled corticosteroids plus long-acting beta2-agonist t

233 that remains uncontrolled despite high-dose inhaled corticosteroids plus other controller medication

234 e screening despite regular use of high-dose inhaled corticosteroids plus other controller medicines.

235 ity, have resulted in a variable approach to inhaled corticosteroid prescribing by medical practition

236 (1:1) to 4 weeks of treatment with extrafine inhaled corticosteroids (QVAR 80 mug, two puffs twice pe

237 Once-daily tiotropium add-on to medium-dose inhaled corticosteroids reduces airflow obstruction and

238 ntervention condition were triggered when an inhaled corticosteroid refill was due or overdue.

239 ol Questionnaire), lung function (FEV1), and inhaled corticosteroid requirement.

240 T gene as a novel pharmacogenetic locus for inhaled corticosteroid response in asthma.

241 g with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmeterol/fluticasone combinatio

242 minimise any adverse effects, treatment with inhaled corticosteroids should always aim to reach the l

243 In contrast, inhaled corticosteroids showed no effect on both T cell

244 loped a brief version (ICQ-S) of the 57-item Inhaled Corticosteroids side-effect Questionnaire (ICQ)

245 r more of blood leucocytes respond better to inhaled corticosteroids than do those with counts of les

246 sthma without symptoms of GER who were using inhaled corticosteroids, the addition of lansoprazole, c

247 In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation

248 Nonadherence to inhaled corticosteroid therapy (ICS) is a major contribu

249 ld to moderate asthma controlled by low-dose inhaled corticosteroid therapy (n = 114 assigned to phys

250 ears to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify pat

251 AMG 853 as an add-on to inhaled corticosteroid therapy demonstrated no associate

252 wth, and that children who receive long-term inhaled corticosteroid therapy for asthma have height de

253 No consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma.

254 able to intervention; long-term therapy with inhaled corticosteroid therapy is safer than frequent bu

255 with inadequately controlled asthma despite inhaled corticosteroid therapy, especially in periostin-

256 e persistent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomar

257 hma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.

258 were no more likely than those treated with inhaled corticosteroids to experience adverse outcomes.

259 be involved in a reduction in the ability of inhaled corticosteroids to impair control of airway infl

260 S sprays to placebo, INCS sprays plus orally inhaled corticosteroids to orally inhaled corticosteroid

261 The results do not support restriction of inhaled corticosteroids to patients with symptoms on mor

262 y inhaled corticosteroids alone, and nasally inhaled corticosteroids to placebo.

263 nts who remained symptomatic despite maximal inhaled corticosteroid treatment (mean FEV(1), 60% of pr

264 randomly assigned 294 patients to extrafine inhaled corticosteroid treatment (n=148) or placebo (n=1

265 In the inhaled corticosteroid treatment group, prebronchodilato

266 omorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermitt

267 58 adult patients with mild asthma having no inhaled corticosteroid treatment, and 10 adult patients

268 nadequate asthma control in children despite inhaled corticosteroid treatment, but it is not known wh

269 patients with asthma who underwent extrafine inhaled corticosteroid treatment, the magnitude of the i

270 with poor asthma control who were receiving inhaled corticosteroid treatment.

271 asthma, to aeroallergen sensitization, or to inhaled corticosteroid treatment.

272 and raised sputum eosinophil counts despite inhaled corticosteroid treatment.

273 in their risk of pneumonia, irrespective of inhaled corticosteroid treatment.

274 s Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid trial were analyzed for individua

275 ponse to Leukotriene Receptor Antagonist and Inhaled Corticosteroid trial).

276 Control Questionnaire score of 1) 0.63; and inhaled corticosteroid use 0.89.

277 Despite the robust association of inhaled corticosteroid use with increased risk of pneumo

278 c characteristics, self-rated health status, inhaled corticosteroid use, and FEV1 /FVC, asthma were a

279 cohort (n = 650), adjusting for smoking and inhaled corticosteroid use, and verified results in thre

280 A history of inhaled corticosteroid use, but not atopic status, mite

281 After a run-in period to control for inhaled corticosteroid use, induced sputum was collected

282 locate patients (1:1; stratified by baseline inhaled corticosteroid use, with the balance of treatmen

283 n those with milder asthma in the setting of inhaled corticosteroid use.

284 sinophilia, neutrophilia, asthma control and inhaled corticosteroid use.

285 xhaled nitric oxide) adjustment, the dose of inhaled corticosteroids was adjusted every 6 weeks; for

286 New use of LABAs and inhaled corticosteroids was associated with a modestly r

287 omarker-based or symptom-based adjustment of inhaled corticosteroids was not superior to physician as

288 Adherence with inhaled corticosteroids was similarly high for both inco

289 and winter, whereas a higher requirement for inhaled corticosteroids was the strongest predictor in s

290 ent asthma diagnosis and prescription for an inhaled corticosteroid were randomized to the computeriz

291 or's diagnosis of asthma who were prescribed inhaled corticosteroids were allocated to one of 3 treat

292 Neither symptoms nor the use of inhaled corticosteroids were predictive of pulmonary fun

293 Thirty-nine adult asthmatics on inhaled corticosteroids were randomized to receive activ

294 The dosages of inhaled corticosteroids were reduced.

295 every 6 weeks; for symptom-based adjustment, inhaled corticosteroids were taken with each albuterol r

296 s of exacerbation had different responses to inhaled corticosteroids when compared with the other clu

297 Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting beta

298 patients with asthma not well controlled on inhaled corticosteroids with or without long-acting beta

299 n exhibit poor control despite high doses of inhaled corticosteroids with or without systemic cortico

300 It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves ou